Jim Mazzola
Investor Relations Contact chez OUTSET MEDICAL, INC.
Profil
Jim Mazzola is currently the Head-Investor Relations at Outset Medical, Inc. Prior to this, he worked as Senior Vice President-Communication at Cardinal Health, Inc. from 2003 to 2008.
He then served as Head-Communication at Halozyme Therapeutics, Inc. and as Senior Vice President-Corporate Marketing at CareFusion Corp.
from 2008 to 2015.
He also worked as Investor Contact at Turning Point Therapeutics, Inc. and as President at CareFusion Foundation.
Mr. Mazzola completed his undergraduate and MBA degrees from the University of Dayton.
Postes actifs de Jim Mazzola
| Sociétés | Poste | Début |
|---|---|---|
| OUTSET MEDICAL, INC. | Investor Relations Contact | 01/01/2022 |
Anciens postes connus de Jim Mazzola
| Sociétés | Poste | Fin |
|---|---|---|
| CAREFUSION CORPORATION | Investor Relations Contact | 01/03/2015 |
| CARDINAL HEALTH, INC. | Public Communications Contact | 01/09/2008 |
| CareFusion Foundation | President | - |
| HALOZYME THERAPEUTICS, INC. | Investor Relations Contact | - |
| TURG POIN | Investor Relations Contact | - |
Formation de Jim Mazzola
| University of Dayton | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CARDINAL HEALTH, INC. | Distribution Services |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| OUTSET MEDICAL, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
CareFusion Corp.
 CareFusion Corp. Medical DistributorsDistribution Services CareFusion Corp. engages in the manufactures of medical equipment and device. The company was founded on February 4, 2009 and is headquartered in San Diego, CA. | Distribution Services |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
| CareFusion Foundation |
